title: Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.
abstract: The melanocortin-4 receptor (MC4R) is a G-protein-coupled receptor (GPCR) that is expressed in the central nervous system and has a role in regulating feeding behavior, obesity, energy homeostasis, male erectile response, and blood pressure. Since the report of the MC4R knockout mouse in 1997, the field has been searching for links between this genetic biomarker and human obesity and type 2 diabetes. More then 80 single nucleotide polymorphisms (SNPs) have been identified from human patients, both obese and nonobese controls. Many significant studies have been performed examining the pharmacological characteristics of these hMC4R SNPs in attempts to identify a molecular defects/insights that might link a genetic factor to the obese phenotype observed in patients possessing these mutations. Our laboratory has previously reported the pharmacological characterization of 40 of these polymorphic hMC4 receptors with multiple endogenous and synthetic ligands. The goal of the current study is to perform a similar comprehensive side-by-side characterization of 30 additional human hMC4R with single nucleotide polymorphisms using multiple endogenous agonists [alpha-, beta-, and gamma(2)-melanocyte stimulating hormones (MSH) and adrenocorticotropin (ACTH)], the antagonist agouti-related protein hAGRP(87-132), and synthetic agonists [NDP-MSH, MTII, and the tetrapeptide Ac-His-dPhe-Arg-Trp-NH(2) (JRH887-9)]. These in vitro data, in some cases, provide a putative molecular link between dysfunctional hMC4R's and human obesity. These 30 hMC4R SNPs include R7H, R18H, R18L, S36Y, P48S, V50M, F51L, E61K, I69T, D90N, S94R, G98R, I121T, A154D, Y157S, W174C, G181D, F202L, A219 V, I226T, G231S, G238D, N240S, C271R, S295P, P299L, E308K, I317V, L325F, and 750DelGA. All but the N240S hMC4R were identified in obese patients. Additionally, we have characterized a double I102T/V103I hMC4R. In addition to the pharmacological characterization, the hMC4R variants were evaluated for cell surface expression by flow cytometry. The F51L, I69T, and A219V hMC4Rs possessed full agonist activity and significantly decreased endogenous agonist ligand potency. At the E61K, D90N, Y157S, and C271R hMC4Rs, all agonist ligands examined were only partially efficacious in generating a maximal signaling response (partial agonists) and possessed significantly decreased endogenous agonist ligand potency. Only the A219V, G238D, and S295P hMC4Rs possessed significantly decreased AGRP(87-132) antagonist potency. These data provide new information for use in GPCR computational development as well as insights into MC4R structure ad function.
authors.affiliation: Department of Pharmacodynamics, University of Florida, Gainesville, Florida 32610, USA.
authors.forename: Zhimin
authors.initials: Z
authors.lastname: Xiang
authors.forename: Bettina
authors.initials: B
authors.lastname: Proneth
authors.forename: Marvin L
authors.initials: ML
authors.lastname: Dirain
authors.forename: Sally A
authors.initials: SA
authors.lastname: Litherland
authors.forename: Carrie
authors.initials: C
authors.lastname: Haskell-Luevano
mesh_terms: D054369:Agouti-Related Protein / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D000595:Amino Acid Sequence; D001667:Binding, Competitive / Q000187:drug effects / Q000235:genetics; D002460:Cell Line; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008024:Ligands; D008297:Male; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009765:Obesity / Q000235:genetics / Q000378:metabolism; D011110:Polymorphism, Genetic; D011333:Pro-Opiomelanocortin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology*; D011485:Protein Binding / Q000187:drug effects / Q000235:genetics; D044105:Receptor, Melanocortin, Type 4 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D000521:alpha-MSH / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D019824:beta-MSH / Q000378:metabolism / Q000494:pharmacology; D019825:gamma-MSH / Q000378:metabolism / Q000494:pharmacology
chemical_list: D054369:Agouti-Related Protein; D008024:Ligands; C470072:MC4R protein, human; D044105:Receptor, Melanocortin, Type 4; D019824:beta-MSH; D019825:gamma-MSH; D000521:alpha-MSH; D011333:Pro-Opiomelanocortin; C027756:MSH, 4-Nle-7-Phe-alpha-
references.citation: Cell. 1997 Jan 10;88(1):131-41
references.pmid: 9019399
references.citation: Cell. 1992 Dec 24;71(7):1195-204
references.pmid: 1473152
references.citation: Nature. 1969 Feb 15;221(5181):667-9
references.pmid: 4304587
references.citation: Science. 1997 Oct 3;278(5335):135-8
references.pmid: 9311920
references.citation: Trends Pharmacol Sci. 1995 Dec;16(12):413-7
references.pmid: 8578614
references.citation: J Med Chem. 2005 Apr 21;48(8):3060-75
references.pmid: 15828845
references.citation: Eur J Pharmacol. 2003 Feb 21;462(1-3):41-52
references.pmid: 12591094
references.citation: Diabetes. 2003 Dec;52(12):2996-3000
references.pmid: 14633862
references.citation: Proc Natl Acad Sci U S A. 1980 Oct;77(10):5754-8
references.pmid: 6777774
references.citation: J Pediatr. 2001 Aug;139(2):204-9
references.pmid: 11487744
references.citation: J Med Chem. 1989 Dec;32(12):2555-61
references.pmid: 2555512
references.citation: Clin Endocrinol (Oxf). 2008 Apr;68(4):529-35
references.pmid: 17941900
references.citation: Arch Int Pharmacodyn Ther. 1974 Mar;208(1):19-23
references.pmid: 4367710
references.citation: J Clin Endocrinol Metab. 2004 Feb;89(2):904-8
references.pmid: 14764812
references.citation: J Clin Endocrinol Metab. 2004 Feb;89(2):940-5
references.pmid: 14764818
references.citation: J Biol Chem. 1980 Aug 10;255(15):7108-17
references.pmid: 6248546
references.citation: J Med Chem. 2001 Jun 21;44(13):2247-52
references.pmid: 11405661
references.citation: J Clin Endocrinol Metab. 2005 Oct;90(10):5632-8
references.pmid: 16030156
references.citation: Mol Endocrinol. 1994 Oct;8(10):1298-308
references.pmid: 7854347
references.citation: Endocrinology. 2009 Jan;150(1):114-25
references.pmid: 18801902
references.citation: Nature. 2007 Nov 15;450(7168):383-7
references.pmid: 17952055
references.citation: Science. 1992 Aug 28;257(5074):1248-51
references.pmid: 1325670
references.citation: Biotechniques. 1988 Jul-Aug;6(7):632-8
references.pmid: 3273409
references.citation: Biochemistry. 2001 May 22;40(20):6164-79
references.pmid: 11352754
references.citation: Biochemistry. 2007 Jul 17;46(28):8273-87
references.pmid: 17590021
references.citation: J Biol Chem. 2003 Jun 20;278(25):22939-45
references.pmid: 12690102
references.citation: Peptides. 2003 Jan;24(1):73-82
references.pmid: 12576087
references.citation: N Engl J Med. 2003 Mar 20;348(12):1085-95
references.pmid: 12646665
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15043-8
references.pmid: 9844012
references.citation: Endocr Rev. 1988 Feb;9(1):159-79
references.pmid: 3286233
references.citation: Regul Pept. 2001 May 5;99(1):1-7
references.pmid: 11257308
references.citation: J Biol Chem. 2002 Dec 6;277(49):47662-70
references.pmid: 12244039
references.citation: Hum Mol Genet. 2003 Jan 15;12(2):145-53
references.pmid: 12499395
references.citation: Nature. 1997 Jan 9;385(6612):165-8
references.pmid: 8990120
references.citation: Ann N Y Acad Sci. 2003 Jun;994:49-57
references.pmid: 12851297
references.citation: J Clin Endocrinol Metab. 2003 Sep;88(9):4258-67
references.pmid: 12970296
references.citation: Diabetes. 2004 Oct;53(10):2696-9
references.pmid: 15448103
references.citation: J Biol Chem. 2003 May 2;278(18):15935-40
references.pmid: 12594226
references.citation: J Med Chem. 2008 Sep 25;51(18):5585-93
references.pmid: 18800761
references.citation: Endocrinology. 1999 Mar;140(3):1408-15
references.pmid: 10067869
references.citation: Biochemistry. 2005 Aug 30;44(34):11329-41
references.pmid: 16114870
references.citation: Nature. 1961 Jan 21;189:176-9
references.pmid: 13761067
references.citation: J Clin Endocrinol Metab. 2002 Oct;87(10):4442-6
references.pmid: 12364415
references.citation: FASEB J. 2009 Sep;23(9):3059-69
references.pmid: 19417090
references.citation: N Engl J Med. 2003 Mar 20;348(12):1096-103
references.pmid: 12646666
references.citation: J Med Chem. 2002 Oct 10;45(21):4589-93
references.pmid: 12361385
references.citation: Int J Obes Relat Metab Disord. 2002 May;26(5):647-51
references.pmid: 12032748
references.citation: Science. 2007 Nov 23;318(5854):1266-73
references.pmid: 17962519
references.citation: Mol Endocrinol. 1999 Jan;13(1):148-55
references.pmid: 9892020
references.citation: Biochemistry. 2006 Jun 13;45(23):7277-88
references.pmid: 16752916
references.citation: Clin Chem. 2005 Aug;51(8):1358-64
references.pmid: 15951321
references.citation: Biochem Biophys Res Commun. 1994 May 16;200(3):1214-20
references.pmid: 8185570
references.citation: Genes Dev. 1993 Mar;7(3):454-67
references.pmid: 8449404
references.citation: Endocrinology. 2003 Oct;144(10):4544-51
references.pmid: 12959994
references.citation: Mol Endocrinol. 2001 Jan;15(1):164-71
references.pmid: 11145747
references.citation: Diabetes. 2002 Jan;51(1):243-6
references.pmid: 11756348
references.citation: Br J Pharmacol Chemother. 1947 Sep;2(3):189-206
references.pmid: 20258355
references.citation: Endocr Rev. 1980 Winter;1(1):1-27
references.pmid: 6262069
references.citation: J Clin Invest. 2000 Jul;106(2):253-62
references.pmid: 10903341
references.citation: J Clin Endocrinol Metab. 2006 May;91(5):1761-9
references.pmid: 16492696
references.citation: Nat Med. 2002 Jul;8(7):643-4
references.pmid: 12091883
references.citation: Trends Pharmacol Sci. 1993 Aug;14(8):303-7
references.pmid: 8249148
references.citation: Anal Biochem. 1995 Apr 10;226(2):349-54
references.pmid: 7793637
references.citation: FEBS Lett. 1992 Sep 14;309(3):417-20
references.pmid: 1516719
references.citation: J Clin Endocrinol Metab. 2005 Jan;90(1):219-24
references.pmid: 15486053
references.citation: Chem Biol Drug Des. 2006 Mar;67(3):215-29
references.pmid: 16611215
references.citation: J Biol Chem. 1993 Jul 15;268(20):15174-9
references.pmid: 8392067
references.citation: J Am Chem Soc. 2002 Sep 18;124(37):11046-55
references.pmid: 12224952
references.citation: Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8856-60
references.pmid: 8415620
references.citation: Hum Mol Genet. 2003 Mar 1;12(5):561-74
references.pmid: 12588803
references.citation: Diabetes. 2003 Dec;52(12):2984-8
references.pmid: 14633860
references.citation: J Urol. 1998 Aug;160(2):389-93
references.pmid: 9679884
references.citation: J Biol Chem. 1997 Sep 12;272(37):23000-10
references.pmid: 9287296
references.citation: Nature. 2001 May 24;411(6836):480-4
references.pmid: 11373681
references.citation: J Med Chem. 2002 Jun 20;45(13):2801-10
references.pmid: 12061882
references.citation: J Biol Chem. 1999 Dec 10;274(50):35816-22
references.pmid: 10585465
references.citation: J Med Chem. 2002 Dec 19;45(26):5736-44
references.pmid: 12477357
references.citation: J Biol Chem. 1993 Apr 15;268(11):8246-50
references.pmid: 8463333
references.citation: J Endocrinol. 2002 Mar;172(3):411-21
references.pmid: 11874690
references.citation: N Engl J Med. 2009 Jan 1;360(1):44-52
references.pmid: 19092146
references.citation: J Med Chem. 2004 Apr 22;47(9):2194-207
references.pmid: 15084118
references.citation: Biochemistry. 2001 Dec 25;40(51):15520-7
references.pmid: 11747427
references.citation: J Med Chem. 2002 Jul 4;45(14):3073-81
references.pmid: 12086493